[Pharmacogenetics MUST become more available , more affordable and more utilized by physicians. the prevalence of individuals with mutations in the detoxifying systems that determine how well a drug is utilized and or cleared from the body have been reported for several of these systems. those with mutations in the CYP450 system as well as any of the transporter protein systems are at untenable risks for adverse drug effects. These mutations are not rare, yet with all this scientific information available, it is not applied to clinical practice. I understand this branch of science is in its infancy; it does not preclude the application of what is known now. I wonder if perverse incentives to delay application of this science occurs within the pharma and insurance industry.